Gene Test Predicts Melanoma Metastases
|
By LabMedica International staff writers Posted on 07 Apr 2014 |

Image: A melanoma on a patient\'s skin (Photo courtesy of the US National Cancer Institute).
A gene expression profile (GEP) test can identify primary cutaneous melanoma tumors that are likely to metastasize in patients who had a negative sentinel lymph node biopsy.
The noninvasive 31-gene GEP test that is widely used to determine metastatic risk in Stage I and II melanoma patients has been compared to sentinel lymph node biopsy (SLNB) which has traditionally been the best prognostic test available for melanoma patients.
Scientists at Castle Biosciences Inc. (Friendswood, TX, USA) compared their test called DecisionDx-Melanoma to results from134 patients with Stage I, II, or III cutaneous melanoma. These 134 patients represented all patients in the initial clinical validation studies who had a documented sentinel lymph node procedure. The DecisionDx-Melanoma is a proprietary test carried out in the company’s laboratories.
In patients with a negative SLNB, a result interpreted as a lower risk for metastasis, the GEP test identified the vast majority of melanomas that ultimately progressed over the subsequent five year period. The rate of five year metastasis-free survival (MFS) was 55% for SLNB negative patients compared to 37% for SLNB positive patients The GEP test results showed improved prognostic accuracy in these same patients with an MFS of 87% for the low-risk (Class 1) patients and 31% for the high risk (Class 2) patients.
The GEP test showed improved prognostic accuracy, with an overall survival (OS) for GEP Class 1 patients of 92% compared to 49% for Class 2 patients. The GEP test was also analyzed in combination with SLNB status. The 20% of patients who had high risk results for both tests (GEP Class 2 and SLNB positive) had lower survival rates (MFS=34%; OS=53%). Similarly, the 31% of patients who had low risk results for both tests (GEP Class 1 and SLNB negative) had higher survival rates (MFS=82%; OS=92%). Importantly, in the 49% of patients who had results that were discordant, high risk outcome for one test, low risk for the other, the GEP test result correctly predicted the patients' clinical outcomes. Net reclassification improvement of GEP class over SLNB status was greater than 50%.
Pedram Gerami, MD, the study author and an associate professor of Dermatology at Northwestern University (Evanston, IL, USA), said, “The results from this study show the GEP test is an independent predictor of metastasis and death, and significantly improves upon sentinel lymph node biopsy for staging melanoma patients. Based upon this data, optimal use of the GEP test may be to identify high risk patients among those with a negative SLNB result, or for patients who are ineligible for or who decline a SLNB procedure.” The study was presented at the 72nd Annual Meeting of the American Academy of Dermatology held March 21-25 2104 in Denver, CO, USA).
Castle Biosciences Inc.
Northwestern University
Related Links:
The noninvasive 31-gene GEP test that is widely used to determine metastatic risk in Stage I and II melanoma patients has been compared to sentinel lymph node biopsy (SLNB) which has traditionally been the best prognostic test available for melanoma patients.
Scientists at Castle Biosciences Inc. (Friendswood, TX, USA) compared their test called DecisionDx-Melanoma to results from134 patients with Stage I, II, or III cutaneous melanoma. These 134 patients represented all patients in the initial clinical validation studies who had a documented sentinel lymph node procedure. The DecisionDx-Melanoma is a proprietary test carried out in the company’s laboratories.
In patients with a negative SLNB, a result interpreted as a lower risk for metastasis, the GEP test identified the vast majority of melanomas that ultimately progressed over the subsequent five year period. The rate of five year metastasis-free survival (MFS) was 55% for SLNB negative patients compared to 37% for SLNB positive patients The GEP test results showed improved prognostic accuracy in these same patients with an MFS of 87% for the low-risk (Class 1) patients and 31% for the high risk (Class 2) patients.
The GEP test showed improved prognostic accuracy, with an overall survival (OS) for GEP Class 1 patients of 92% compared to 49% for Class 2 patients. The GEP test was also analyzed in combination with SLNB status. The 20% of patients who had high risk results for both tests (GEP Class 2 and SLNB positive) had lower survival rates (MFS=34%; OS=53%). Similarly, the 31% of patients who had low risk results for both tests (GEP Class 1 and SLNB negative) had higher survival rates (MFS=82%; OS=92%). Importantly, in the 49% of patients who had results that were discordant, high risk outcome for one test, low risk for the other, the GEP test result correctly predicted the patients' clinical outcomes. Net reclassification improvement of GEP class over SLNB status was greater than 50%.
Pedram Gerami, MD, the study author and an associate professor of Dermatology at Northwestern University (Evanston, IL, USA), said, “The results from this study show the GEP test is an independent predictor of metastasis and death, and significantly improves upon sentinel lymph node biopsy for staging melanoma patients. Based upon this data, optimal use of the GEP test may be to identify high risk patients among those with a negative SLNB result, or for patients who are ineligible for or who decline a SLNB procedure.” The study was presented at the 72nd Annual Meeting of the American Academy of Dermatology held March 21-25 2104 in Denver, CO, USA).
Castle Biosciences Inc.
Northwestern University
Related Links:
Latest Molecular Diagnostics News
- Blood RNA Patterns Linked to CAR T-Cell Response and Survival in Lymphoma
- Genome Sequencing Provides Clues to Unexplained Recurrent Miscarriages
- Multimodal AI Blood Test Aims to Improve Early Lung Cancer Screening
- Protein-Based Classifier Shows Promise for Predicting Melanoma Treatment Outcomes
- Liquid Biopsy Gains FDA Approval to Guide Breast Cancer Combination Therapy
- FDA Clears Three-Virus Respiratory Panel for Anterior Nasal Swabs
- Whole Transcriptome Analysis Expands Understanding of Cancer Gene Fusions
- Fapon Showcases AI-Engineered Enzymes and RNA Workflows at AMP 2026
- AMP 2026 Underscores Molecular Testing’s Role in Precision Medicine for Women’s Health
- Target-Amplification-Free CRISPR Platform Demonstrates Molecular Detection in Under 10 Minutes
- Genetic Test Improves Risk Prediction for Open-Angle Glaucoma
- Epigenetic Blood Test Detects Early Breast Cancer and Predicts Recurrence Risk
- Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment
- Lung Cancer Atlas Reveals Cellular Patterns Associated With Patient Prognosis
- AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026
- AMP 2026 Highlights Advances in Molecular Testing for Pediatric Diseases
Channels
Clinical Chemistry
view channelAI and Nanotechnology Enable Five-Minute Urine Drug Screening
Rapid screening for illicit drugs remains challenging when testing must be performed at the point of care. Laboratory methods provide accurate results but require sample preparation and specialized equipment,... Read more
Study Questions Uniform Stool-Test Cutoff Across Age Groups
Colorectal cancer remains a major clinical challenge, ranking as the fourth most common cancer and the second-leading cause of cancer death in the U.K. Early-onset colorectal cancer, defined as diagnosis... Read moreHematology
view channel
Werfen Gains FDA Clearance for ROTEM sigma Cartridge Use in Trauma
Traumatic injuries account for approximately 10% of deaths worldwide, with uncontrolled bleeding remaining a leading cause of potentially preventable trauma-related death. Trauma-induced coagulopathy further... Read more
Serial Blood Samples Reveal Leukemia’s Evolution Decades Before Diagnosis
Acute myeloid leukemia (AML) is an aggressive blood cancer affecting approximately 2,700 people in the U.K. annually, with only about one in six patients surviving five years after diagnosis.... Read moreImmunology
view channel
Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice
Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more
Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis
Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more
Antibody Testing Informs Melioidosis Diagnosis and Surveillance in Emerging Regions
Melioidosis is a serious and sometimes fatal infection caused by the soil- and water-dwelling bacterium Burkholderia pseudomallei. People and animals can contract the disease through exposure to contaminated... Read moreMicrobiology
view channel
WHO Survey Reveals Gaps in Antimicrobial Resistance Testing and Response
Antimicrobial resistance (AMR) remains a major challenge for health systems, limiting effective treatment options for drug-resistant infections. These infections caused more than 1 million deaths and contributed... Read more
Direct-From-Specimen Pneumonia Test Detects Pathogens and Resistance in Hours
Pneumonia is a leading cause of sepsis and is associated with high mortality. Conventional culture-based pathogen identification and antimicrobial susceptibility testing can take two to four days, delaying... Read morePathology
view channel
Researchers Evaluate Automated Tissue Analysis Across Four Cancer Types
Histopathology image analysis plays a central role in cancer diagnosis, but tumor tissue can vary considerably across different regions of the same specimen. Pathologists examine cellular morphology, nuclear... Read more
AI Prostate Cancer Test Added to NCCN Guidelines for Post-Surgery Recurrence
Following radical prostatectomy, an estimated 20% to 40% of prostate cancer patients develop biochemical recurrence, marked by rising prostate-specific antigen levels that may indicate cancer recurrence.... Read more
New Training Approach Helps AI Distinguish Neighboring Cells in Tissue
Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more
Review Highlights Progress and Validation Needs for AI in Digital Pathology
Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read moreTechnology
view channel
Experimental Blood Test Detects Markers of Three Cancers and Alzheimer’s Disease
Colorectal cancer, glioblastoma, pancreatic cancer, and Alzheimer’s disease are serious conditions in which earlier detection may improve clinical outcomes. Blood-based testing could help identify dis... Read more
New qPCR Master Mixes Offer Broad Compatibility for Routine Research
Quantitative PCR (qPCR) workflows require consistent reagent performance across instruments and assay formats. Laboratories must also manage costs without changing established protocols.... Read moreIndustry
view channel
Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil
Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more







